Czech National Bank Increases Stock Position in Cencora, Inc. (NYSE:COR)

Czech National Bank lifted its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 12.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 35,536 shares of the company's stock after purchasing an additional 3,990 shares during the period. Czech National Bank's holdings in Cencora were worth $7,998,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in COR. Fisher Asset Management LLC acquired a new position in Cencora in the 4th quarter valued at approximately $244,000. Trust Co. of Vermont acquired a new position in shares of Cencora in the 4th quarter worth approximately $62,000. Wahed Invest LLC bought a new stake in shares of Cencora in the 4th quarter valued at $567,000. Vanguard Group Inc. bought a new stake in Cencora during the fourth quarter valued at $4,212,508,000. Finally, M3 Advisory Group LLC bought a new stake in shares of Cencora during the 4th quarter valued at about $243,000. Institutional investors and hedge funds own 97.52% of the company's stock.

Cencora Stock Performance

Shares of Cencora stock traded up $0.36 during mid-day trading on Friday, hitting $222.56. 937,763 shares of the stock were exchanged, compared to its average volume of 1,413,334. The company has a market capitalization of $44.39 billion, a P/E ratio of 24.35, a P/E/G ratio of 1.40 and a beta of 0.44. The company has a debt-to-equity ratio of 3.93, a quick ratio of 0.55 and a current ratio of 0.89. The company has a 50-day simple moving average of $232.97 and a 200 day simple moving average of $231.48. Cencora, Inc. has a 12 month low of $182.75 and a 12 month high of $247.66.

Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.18 by $0.16. The firm had revenue of $74.20 billion during the quarter, compared to analyst estimates of $73.32 billion. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The business's revenue was up 10.8% compared to the same quarter last year. During the same period last year, the firm posted $2.92 EPS. Sell-side analysts anticipate that Cencora, Inc. will post 13.63 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 9th were given a $0.51 dividend. This represents a $2.04 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date was Friday, August 9th. Cencora's dividend payout ratio is currently 22.32%.

Analysts Set New Price Targets

Several brokerages have recently commented on COR. StockNews.com downgraded shares of Cencora from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 20th. Wells Fargo & Company increased their price objective on shares of Cencora from $236.00 to $249.00 and gave the stock an "equal weight" rating in a research report on Thursday, August 1st. Robert W. Baird decreased their target price on Cencora from $287.00 to $283.00 and set an "outperform" rating for the company in a research report on Friday, September 6th. Evercore ISI reduced their price objective on Cencora from $270.00 to $250.00 and set an "outperform" rating for the company in a research note on Tuesday. Finally, Bank of America reissued a "neutral" rating and issued a $245.00 price target (down previously from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Cencora currently has a consensus rating of "Moderate Buy" and a consensus target price of $259.44.

Insiders Place Their Bets

In other news, EVP Silvana Battaglia sold 1,473 shares of the stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total transaction of $357,482.37. Following the completion of the transaction, the executive vice president now owns 10,948 shares in the company, valued at approximately $2,656,970.12. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, EVP Silvana Battaglia sold 1,473 shares of the firm's stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total value of $357,482.37. Following the completion of the transaction, the executive vice president now directly owns 10,948 shares of the company's stock, valued at approximately $2,656,970.12. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the business's stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the sale, the insider now directly owns 19,980,000 shares in the company, valued at $4,806,388,800. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 4,450,399 shares of company stock valued at $1,070,392,799 over the last ninety days. 15.80% of the stock is currently owned by insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.